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Thymidylate synthase (TS; EC 2.1.1.45) is a critical enzyme in the
de novo synthesis of thymidylate (dTTP) and has long been recog-
nized as a target for chemotherapeutic intervention. Of interest has
been a class of quinazoline-based compounds that fall into three
general biochemical sub-type of antifolate TS inhibitor; those
which:
1. are transported into the cell via the reduced folate carrier
(RFC) and are subsequently polyglutamated by folylpolygluta-
mate synthetase (FPGS; EC 6.3.2.17), e.g. TomudexTM
(raltitrexed; ZD1694; reviewed in Jackman et al, 1996a)
2. use the RFC but which do not undergo intracellular polygluta-
mation, e.g ZD9331 (Jackman et al 1995c, 1997a)
3. do not interact with the RFC or FPGS, which may either retain
the ‘classical’ (glutamate-containing) structure of antifolates
(Bavetsias et al, 1997; Jackman et al, 1997b; Melin et al, 1997)
or be ‘non-classical’ lipophilic derivatives (Skelton et al,
1994a, 1994b).
This latter sub-type was originally developed with the aim of
achieving good TS inhibition whilst circumventing resistance due
to defective RFC and/or polyglutamation mechanisms in tumours.
Based on the structure of ZM198583 (2-desamino-2-methyl-N10-
propargyl-5,8-dideazafolic acid; Jackman et al, 1991), these
compounds have an aminomethyl 2-, 3- or 4-pyridine in place of
the glutamate residue (Skelton et al, 1997). Their highly lipophilic
nature [LogP (partition coefficient) ~ 3.5] suggests that they are
likely to enter the cell by passive diffusion, and the absence of the
glutamate ligand precludes intracellular polyglutamation.
The pyridine derivatives were generally good inhibitors of
isolated mammalian TS (IC50 ~ 0.1–2 mM). However, although
compounds with the 2- or 4-pyridine structure targeted TS (at least
partially) in W1L2 human lymphoblastoid cells, those with the
3-pyridine configuration did not, since they were active in the
presence of exogenous salvageable thymidine (dThd; Jackman
et al, 1996b; Skelton et al, 1997). They were also active against
cell lines resistant to antifolates due to elevated TS or dihydro-
folate reductase (DHFR) enzyme levels (Skelton et al, 1997).
Furthermore, there were analogues in the 3-pyridine series which
were extremely potent inhibitors of in vitro tumour cell growth
(IC50 ~ 1 nM). For example, substitution with Cl or Br at the C7
position of the quinazoline ring was found to improve growth
inhibitory potency against L1210 and W1L2 cell lines by
~ 100-fold (Skelton et al, 1997). A detailed account of
structure–activity relationships will be given elsewhere (Skelton
et al, manuscript in preparation). Thus, based on its good growth
inhibitory potency (W1L2 72 h IC50 = 0.0028 mM) and apparently
folate-independent mechanism, the 7-bromo-3-pyridine derivative
CB30865 (ZM242421, p-[N-(7-bromo-3,4-dihydro-2-methyl-4-
oxoquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]-N-(3-pyridyl-
methyl)benzamide; Figure 1) was selected for further in vitro
studies.
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Summary Three lipophilic quinazoline-based aminomethyl pyridine compounds, which differ only in the position of the nitrogen in their
pyridine ring, are described. CB300179 (2-pyridine), CB300189 (4-pyridine) and CB30865 (3-pyridine) all inhibited isolated mammalian TS
with IC50 values of 508, 250 and 156 nM respectively. CB30865 was the most potent growth inhibitory agent (IC50 values in the range 1–
100 nM for several mouse and human cell types). CB300179 and CB300189 were active in the micromolar range. Against W1L2 cells,
CB300179 and CB300189 demonstrated reduced potency in the presence of exogenous thymidine (dThd), and against a W1L2:C1 TS
overproducing cell line. In contrast, CB30865 retained activity in these systems. Furthermore, combinations of precursors and end products
of folate metabolism, e.g. dThd/hypoxanthine (HX) or leucovorin (LV), did not prevent activity. CB30865 did not interfere with the incorporation
of tritiated dThd, uridine or leucine after 4 h. A cell line was raised with acquired resistance to CB30865 (W1L2:R865; > 200-fold), which was
not cross-resistant to CB300179 or CB300189. In addition, W1L2:R865 cells were as sensitive as parental cells to agents from all the major
chemotherapeutic drug classes. CB300179 and CB300189 induced an S phase accumulation (preventable by co-administration of dThd). No
cell cycle redistribution was observed following exposure (4–48 h) to an equitoxic concentration of CB30865. In the NCI anticancer drug-
discovery screen, CB30865 displayed a pattern of activity which was not consistent with known anti-tumour agents. These data suggest that
CB30865 represents a class of potent potential anti-tumour agents with a novel mechanism of action.
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This paper presents the in vitro activity of CB30865 in terms
of inhibition of both isolated and whole cell TS, growth
inhibitory/cytotoxic potency (including the influence of co-incu-
bation with combinations of end products and precursors of folate
metabolism), effects on DNA/RNA/protein synthesis (as deter-
mined by incorporation of radiolabelled precursors), generation of
acquired resistance and cross-resistance studies, cell cycle effects
as determined by flow cytometry, and activity in the NCI in vitro
anticancer drug discovery screen. Where appropriate, CB30865
is compared with its 2- and 4-pyridine equivalents CB300179
and CB300189 respectively (Figure 1). The evidence presented
suggests that CB30865, differing only in the position of the
nitrogen in the pyridine ring, is a potent cytotoxic agent with a
unique profile of anti-tumour activity via a folate-independent
target, and delayed non-phase specific effects on the cell cycle.
MATERIALS AND METHODS
Compounds
CB30865 (ZM242421), CB300179 (ZM249148) and CB300189
(ZM249081) were synthesized at ZENECA Pharmaceuticals,
Macclesfield, Cheshire, UK. They were solubilized in dimethyl
sulphoxide (DMSO) at 20 mM and dilutions were made in the
same solvent. Stock solutions were stored at –20°C for a
maximum of 6 months. The TS inhibitor ZD1694 (ZENECA
Pharmaceuticals) and the DHFR inhibitor methotrexate (MTX;
Sigma Chemical Co., Poole, Dorset, UK) were prepared as 10 mM
stock solutions in 0.15 M sodium bicarbonate and diluted in
RPMI-1640 (Life Technologies, Paisley, UK).
Inhibition of mammalian L1210 TS
The inhibition of mouse TS using enzyme partially purified from
the L1210:C15 TS-overproducing cell line (Jackman et al, 1986)
was determined using a previously described method (Calvert
et al, 1980; Jackman et al, 1984). The IC50 against TS (defined as
the concentration of drug required to inhibit the reaction rate by
50% at a (R,S)-5,10-CH2FH4 cofactor concentration of 200 mM)
was determined. The values of Ki (constant for the dissociation of
the inhibitor from the enzyme-inhibitor complex; TS.dUMP.I) and
Kies (constant for the dissociation of the inhibitor from the enzyme-
inhibitor-substrate complex; TS.dUMP.5,10-CH2FH4.I) were
determined by Dr W Ward at ZENECA Pharmaceuticals (Ward et
al, 1992).
Cell culture and growth inhibition assays
W1L2 human lymphoblastoid, W1L2:C1 (elevated TS; O’Connor
et al, 1992) L1210 mouse leukaemia and L5178Y TK+/– mouse
lymphoma (Stephens et al, 1993) cells were cultured in suspen-
sion, and CHI, A2780, PXN94, 41M, HX62, SKOV3 (human
ovarian carcinoma), MCF-7 (human breast carcinoma), HT29 and
SW480 (human colon carcinoma) cell lines were grown as mono-
layers as previously described (Jackman et al, 1990, 1995a). All
cell lines were screened routinely for Mycoplasma using the
Stratagene PCR method (Stratagene Ltd, Cambridge, UK).
Growth inhibition studies with suspension cells were performed
as previously described (Jackman et al, 1990). Activity against the
adherent cell lines was assessed by MTT assay (Twentyman et al,
1987) where cells were seeded in 96-well plates at 1000–3000
cells per well, incubated overnight and then exposed to the appro-
priate drug concentrations for 96–120 h. IC50 values represented
the concentration of drug required to inhibit cell growth/reduce
absorbance at 540 nm to 50% control.
Protection studies
Growth inhibition assays as described above were performed in
W1L2 cells where CB30865 was incubated in the absence and pres-
ence of combinations of precursors and end products of
folate metabolism. The combinations were as follows (all purchased
from Sigma Chemical Co., unless otherwise stated); dThd,
dThd–HX, leucovorin (LV; David Bull Laboratories, Warwick, UK),
dThd–LV, S-adenosylmethionine (SAM), dThd–SAM, dThd–adeno-
sine–guanosine, adenosine–guanosine–inosine, dThd–adenosine–
deoxycoformycin (NCI, Bethesda, MD, USA), dThd–HX–methio-
nine, or dThd–HX–glycine. All components were at 10 mM except
HX (50 mM), LV (50 mM), SAM (15 mM), deoxycoformycin (1 mM),
methionine (1 mM) and glycine (100 mM). Protection studies in the
adherent cell lines were also performed by adding 10 mM dThd or 10
mM dThd–50 mM HX to the medium.
Trypan blue viability studies
W1L2 cells (5 ´ 104 cells ml–1) were treated with 0.006, 0.03 and
0.15 mM CB30865 (equivalent to 2 ´, 10 ´, and 50 ´ IC50 as deter-
mined by 72 h growth inhibition assay). Controls were treated
with 0.5% DMSO. At the appropriate time, aliquots (0.5–3 ml)
were counted on a Coulter counter, centrifuged at 900 g for 5 min
and resuspended in phosphate-buttered saline (PBS) (pH 7.2) such
that 50–200 cells could be counted on a haemocytometer. The cells
were then Coulter counted again so that any losses due to centrifu-
gation could be calculated. The PBS suspension was mixed with
trypan blue (Sigma Chemical Co.) to give a final concentration of
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Figure 1 Structure of CB300179 (2-pyridine), CB30865 (3-pyridine) and
CB300189 (4-pyridine)0.1%, left at room temperature for 5 min and scored on a haemo-
cytometer. Both non-stained (viable) and stained (non-viable) cells
were scored and counts were corrected for percentage recovery on
centrifugation (50–100%).
Clonogenic assay
Cytotoxic potency was determined in W1L2 cells by clonogenic
assay in 96-well plates. Cells (1–3 ´ 105 ml–1) were exposed in
duplicate to 0.03 mM CB30865 for 24 h in T25 Nunc tissue culture
flasks. The cells were then harvested by centrifugation at 900 g for
5 min, resuspended in fresh medium and Coulter Counted. The
cells were then diluted (in several steps) in 50% conditioned
medium (obtained by centrifugation of cells grown to 2–5 ´ 105
ml–1 at 900 g for 5 min and sterile filtered through a 0.2 mm nylon
filter) to a concentration of 1.6 cells ml–1 (controls) or 5 cells ml–1
(treated) and 200 ml was added to each well of the plate. Control
cells were seeded in seven plates (such that no fewer than 50
colonies would be counted at the end of the experiment, since the
plating efficiency was 41 ± 22%) and treated cells were seeded in
two plates. The plates were incubated at 37°C in a humidified
atmosphere. After 2–3 weeks, colonies were visualized by the
addition of 50 ml 2 mg ml–1 MTT (Sigma Chemical Co.). All
colonies consisted of > 50 cells. Colony formation of treated cells
was expressed as a percentage of untreated cells.
Clonogenic assays were also performed in the HT29 human
colon tumour cell line, where cells were exposed to 1 mM
CB30865 for 4–72 h. With the same sample of cells, IC50 values
for CB30865 were determined in the presence and absence of 10
mM dThd by 5-day MTT assay. This was to ensure that CB30865
was not acting as a TS inhibitor at a concentration of 1 mM. Cells
were seeded at 5 ´ 104 ml–1 in T25 vented flasks, incubated
overnight and treated in duplicate with 1 mM CB30865 for 4–72 h
(controls were treated with 0.5% DMSO). At the appropriate time,
the cells were harvested by trypsinization followed by centrifuga-
tion at
900 g for 10 min. The cells were then resuspended in PBS,
counted on a haemocytometer and seeded in triplicate into T25
vented flasks at 300 or 3000 cells per flask. After ~ 2 weeks,
colonies (> 20 cells) were visualized with 5 mg ml–1 MTT and
counted. Plating efficiencies for controls were calculated
(56–99%) and colony formation in the treated samples was deter-
mined as percent of control.
Flux through TS in intact cells
TS activity in intact W1L2 cells was determined by measuring
the rate of 3H2O release, which occurs as a consequence of
flux through TS in cells exposed to [5-3H]dUrd (Moravek
Biochemicals Inc., Brea, CA, USA). This was performed as previ-
ously described (Jackman et al, 1995b).
Incorporation of radiolabelled precursors into acid-
precipitable material
The rate of incorporation of [methyl-3H]dThd, [5-3H]Urd and
L-[4,5-3H]Leu (all purchased from Amersham Int. plc) into
acid-precipitable material was investigated in order to determine
the effects of CB30865 on DNA, RNA and protein synthesis
respectively. W1L2 cells (2 ´ 105 ml–1) were exposed to 0.03 mM
CB30865 for 1–14 h. After the appropriate exposure period, the
cells were Coulter counted and [methyl-3H]dThd, [5-3H]Urd or
L-[4,5-3H]Leu was added to give final dThd and Urd concentra-
tions of 0.2 mM, sp. act. 5 nCi pmol–1, and a final Leu concentration
of 2.2 nM, sp. act. 150 nCi pmol–1. Cells were harvested
(3  ´ 1 ml aliquots) after 15, 30, 45 and 60 min incubation with
radiolabel by centrifugation at 10 000 rpm for 1 min (microfuge)
and resuspension in 100 ml deionized H2O. DNA/RNA/protein
was precipitated on ice by the addition of 1.5 ml ice-cold 2% v/v
PCA. After 10 min on ice, the acid-precipitable material was
washed in 1.5 ml 2% vv PCA, resuspended in 1 ml 10% v/v PCA,
and heated to 80°C for 60 min. The samples were then counted in
Ultima Gold Scintillant, and the data fitted to a linear regression.
The slope was proportional to the rate of incorporation of the
radiolabelled precursor in terms of dpm per number of cells. This
was standardized to give a rate in pmol min–1 per 106 cells.
Generation of acquired resistance to CB30865 and
cross-resistance studies
A cell line was raised with acquired resistance to CB30865,
denoted W1L2:R865, by stepwise selection over ~ 9 months.
Initially, W1L2 cells were incubated with 0.002 mM CB30865
(72 h IC50 = 0.0028 mM), which was raised in small increments
(< twofold) until the cells became resistant to 0.03 mM. When
larger increments were attempted, the cells did not survive. This is
in contrast to generation of a resistant line to the 2-pyridine deriv-
ative, CB300179 (Kobayashi et al, 1995), where the concentration
of the latter could be raised in increments of at least twofold. The
generated W1L2:R865 cell line was routinely cultured in 0.03 mM
CB30865 under the same conditions as W1L2 cells, with cells
being grown in the absence of CB30865 for ~ 2 weeks before an
experiment.
The activity of a number of clinical and experimental anticancer
and cytotoxic agents (refer to Table 2) against W1L2 and
W1L2:R865 cells was determined within parallel experiments by
72 h growth inhibition assay (Coulter counts). CB30865 was
included in every experiment as an internal control. The resistance
factor (RF) for each compound (IC50 W1L2:R865 cells/IC50 W1L2
cells) was then calculated. All compounds were purchased from
Sigma Chemical Co. except trimetrexate (TMQ; supplied by the
NCI), metoprine (supplied by Wellcome Labs, Beckenham, Kent,
UK), lometrexol (supplied by Eli Lilly Laboratories, Indianapolis,
IN, USA), 2¢-deoxycoformycin (supplied by the NCI), doxo-
rubicin (purchased from Farmitalia CarloErba Ltd, Milton
Keynes, Bucks, UK), cisplatin (synthesized by Johnson Matthey
Technology Centre, Reading, Berks, UK), bleomycin (purchased
from Lundbeck Ltd, Luton, Beds, UK), trimelamol (synthesized
by Warner Lambert, Ann Arbor, MI, USA, under contract to the
NCI and supplied as a gift to the NCI) and taxol (supplied by
Bristol-Myers-Squibb, Princeton, NJ, USA).
Flow cytometry
DNA histograms were obtained as previously described
(Ormerod, 1994). W1L2 (at 1–2 ´ 105 ml–1) and CH1 (at 5 ´ 104
ml–1) cells were incubated with drug over a 48-h time course. For
protection studies, the cells were incubated with both drug and 10
mM dThd or 10 mM dThd–50 mM HX. Data were collected on one
of two systems: (1) an Ortho Cytofluorograph 50H equipped with
1694 LA Skelton et al
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a Spectraphysics argon-ion laser. The Ortho Cytofluorograph was
associated with an Ortho 2150 computer system, and the data were
transferred to an IBM compatible PC and analysed using software
written by Dr Michael G Ormerod; (2) a Coulter EPICS Elite ESP
equipped with the laser described above. Data were analysed using
Multicycle software by Phoenix Flow Systems (Oregon, USA).
NCI anticancer drug discovery screen
Screening was carried out by the Developmental Therapeutics
Program, Division of Cancer Treatment, Diagnosis and Centres,
NCI. In this way, the activity of CB30865 was determined against
panels of human tumour cell lines by 48-h sulforhodamine B
(SRB) assay as previously described (Boyd, 1989; Boyd et al,
1992; Monks et al, 1991). For each cell line, three response para-
meters were calculated; GI50, TGI and LC50. The GI50 represents
the concentration of CB30865 required to reduce net cell growth
to 50% control after 48 h. The TGI represents the concentration of
CB30865 required to achieve a percentage growth of zero after
48 h. The LC50 represents the concentration of CB30865 required
to cause a net 50% reduction in SRB staining (i.e. cellular protein)
after 48 h (i.e a net 50% loss of cells). These parameters were
ranked in terms of deviation from the mean (denoted mean graphs;
Paull et al, 1989). ‘COMPARE’ analysis was used to compare the
spectrum of activity of CB30865 with that of standard anticancer
agents of known mechanisms of action, generating Pearson corre-
lation coefficients which describe the degree of similarity of
CB30865 to these agents.
RESULTS
Inhibition of isolated TS
CB300179 (2-pyridine), CB30865 (3-pyridine) and CB300189
(4-pyridine) inhibited isolated mammalian TS with IC50 values of
508, 156 and 250 nM respectively. The Ki and  Kies values for
CB300179 were 160 and 350 nM, respectively, indicating mixed
non-competitive inhibition. CB30865 also inhibited TS in a non-
competitive manner (Ki = 110 nM @ Kies). ZM198583 is reported to
inhibit TS with an IC50 of 50 nM (Ki = 10 nM; Jackman et al,
1991).
Table 1 Growth inhibitory activity of the 3-pyridine derivative CB30865
against some rodent and human tumour cell linesa
Cell line Origin CB30865 IC50 (mM)
W1L2 Human lymphoblastoid 0.0028 ± 0.00050b
L1210 Mouse leukaemia 0.074 ± 0.033c
L5178Y Mouse lymphoma 0.013 ± 0.0089
MCF-7d Human breast tumour 0.0025 ± 0.00065
HT29d Human colon carcinoma 0.026 ± 0.0058
SW480d Human colon carcinoma 0.024 ± 0.00080
Various Human ovarian carcinoma 0.0021 to > 1e
aActivity determined by growth inhibition assays as described in Materials and
Methods. b ± SD (n ³ 3). cNo protection with dThd at a single concentration
equivalent to 10 ´ IC50 (Skelton et al, manuscript in preparation. dAlso tested
in the presence of dThd or dThd/HX (refer to text). eRefer to Figure 2 and text.
Figure 2 Representative growth inhibition curves from human ovarian
carcinoma cells exposed to CB30865, CB300179 or CB300189. Cells were
incubated with the indicated concentrations of drug for 96 h and growth
inhibition was assessed by MTT assay: 41M (n); A2780 (s); CH1 (t); HX62
(u); PXN94 (l); SKOV3 (n n). CB300189 inhibited CH1, A2780 and PXN94
cell growth with IC50 values of 0.43 ± 0.18, 1.1 ± 0.56 and 1.5 mM (mean,
n = 2) respectively. CB30865 inhibited CH1, A2780, PXN94 and SKOV3
cell growth with IC50 values of 0.0021 ± 0.00044, 0.0025 ± 0.00040,
0.0054 ± 0.0023 and 0.0099 ± 0.0029 mM respectively
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Inhibition of cell growth and protection studies
The activity of CB300179, CB300189 and CB30865 against
W1L2 human lymphoblastoid cells was 0.58, 0.27 and 0.0028 mM
respectively (published as part of a Table in Skelton et al, 1997).
CB30865 was further tested against a range of other rodent and
human tumour cell lines (Table 1). Some cell lines were exquis-
itely sensitive (e.g MCF-7, IC50 = 0.0025 mM), whilst others were
relatively resistant (e.g L1210, IC50 = 0.074 mM).
With regard to the panel of ovarian carcinoma cell lines (Figure
2), CB300179 was relatively inactive with all IC50 values > 1 mM.
CB300189 was active at the submicromolar level only against two
cell lines (CH1 and A2780). In contrast, four of the ovarian cell
lines were highly sensitive to CB30865, with IC50 values of
2.1–9.9 nM (CH1, A2780, PXN94 and SKOV3).
Cell viability studies and clonogenic assay
Trypan blue staining was used as an indication of cell viability
following incubation of W1L2 cells with 0.006–0.15 mM CB30865
over ~ 2 weeks. At a concentration of 0.006 mM (2 ´ IC50 as deter-
mined by 72 h growth inhibition assay), the viable cell concentra-
tion increased at the same rate as controls over 24 h. After this
time, there was some growth up to 48 h but it was less than
controls, and the number of viable cells gradually reduced to < 3%
of total cells after 168 h (~ 12-fold lower than the initial viable cell
count). At the higher concentrations of 0.03 and 0.15 mM (equiva-
lent to 10 and 50 ´ 72 h IC50 respectively), proliferation was again
similar to controls for 24 h (although cells treated with 0.15 mM
CB30865 grew slightly less), after which time there was no further
increase in cell number. Population viability decreased to below
the initial viable cell count after 71 h exposure and was eventually
reduced to zero after 168 h. Although CB30865-treated cell popu-
lations were still largely viable after 24 and 48 h, it would appear
that they may be destined to die since a 24 h exposure to 0.03 mM
CB30865-inhibited colony formation by 95 ± 4.5% compared to
untreated controls (data not shown).
Clonogenic assays were also performed in HT29 human colon
carcinoma cells at a concentration of 1 mM CB30865. It was
confirmed that CB30865 did not act via TS at this concentration by
5-day MTT assay in the absence and presence of dThd (data not
shown). Colony formation was comparable to controls after 4 h
exposure, but was reduced to ~ 60% after 24 h exposure. A greater
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Figure 3 Effect of CB30865, CB300179 and CB300189 on flux through TS
in intact W1L2 cells. Cells were treated with 0.03 mM CB30865, 5.0 mM
CB300179 or 2.7 mM CB300189 for 1 or 4 h and TS inhibition was determined
by the rate of 3H2O release that occurs as a consequence of flux through TS
in cells incubated with [5-3H]dUrd. Mean control values were 1.45 ± 0.322
(1 h) and 1.38 ± 0.278 (4 h) pmole min–1 per 106 cells. Experiments were
performed at least in duplicate. Error bars represent S.D.
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Figure 4 W1L2 protection studies with MTX, ZD1694, CB300179 and
CB30865. Cells were co-incubated for 72 h with CB30865 (0.03 mM),
CB300179 (5.8 mM), MTX (0.1 mM) or ZD1694 (0.04 mM) and protection
combinations shown. Inhibition of cell growth was assessed by Coulter
counts
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degree of inhibition of colony formation was observed after 48 h
(~ 70%) and 72 h (> 99%). Thus against these cells, cytotoxicity
was time-dependent.
Inhibition of TS in intact W1L2 cells
At concentrations equivalent to 10 ´ 72 h IC50, the 2- and 4-pyri-
dine derivatives CB300179 (5 mM) and CB300189 (2.7 mM)
respectively caused a reduction in the rate of product (3H2O)
formation (i.e. TS activity) to < 4% control after 1 and 4 h expo-
sure (Figure 3). In contrast, TS activity was maintained at control
levels after 1 and 4 h exposure to 0.03 mM CB30865.
Incorporation of radiolabelled precursors into acid
precipitable material
The incorporation of [methyl-3H]dThd, [5-3H]Urd and L-
[4,5-3H]Leu was unaffected after W1L2 cells were exposed to
Table 2 Cross-resistance studies in W1L2 versus W1L2:R865 cell linesa
Class: Agent IC50 (mM)
W1L2 W1L2:R865 RFb
Antimetabolites
CB300179 0.58 ± 0.15c 0.82, 1.4 1.9
CB300189 0.24 ± 0.017 0.47 ± 0.11d 2.0
5-Fluorodeoxyuridine 0.0049 ± 0.0013 0.0060 1.2
5-Fluorouracil 5.4 8.0 1.5
6-Mercaptopurine 4.7 3.0 0.6
Cytosine arabinoside 0.042, 0.047 0.020, 0.020 0.5
Metoprine 0.031 ± 0.0030 0.019, 0.052 1.2
Deoxycoformycin 0.00042 0.00012 0.3
Lometrexol 0.032, 0.062 0.060, 0.094 1.8
MTX 0.023, 0.0096 0.023 1.4
Mycophenolic acid 0.23 0.27 1.2
Thioguanine 0.14 0.13 0.9
Trimetrexate 0.0030 0.0040 1.3
ZD1694 (TomudexTM) 0.0043 ± 0.00048 0.0046, 0.0030 1.1
DNA interactive agents
Doxorubicin 0.013 ± 0.0045 0.016, 0.026 1.6
Bleomycin 1.0, 3.7 0.32, 0.32 0.5
Camptothecin 0.0020 0.0026 1.1
Chlorambucil 2.1, 1.7 4.2, 2.0 1.6
Cisplatin 0.76, 0.48 0.52, 0.70 1.0
Etoposide 0.017 0.019 1.1
Mitomycin C 0.019, 0.018 0.047, 0.025 1.9
Trimelamol 26 31 1.2
Spindle poisons
Taxol 0.0066 0.0072 1.1
Vinblastine 0.0058 0.0090 1.6
Protein kinase/phosphatase inhibitors
Okadaic acid 0.014, 0.014 0.0068, 0.0076 0.5
Sodium vanadate 8.0 7.0 0.9
Staurosporine 0.031 0.050 1.6
Metabolic poisons
Antimycin A 0.0072 0.0063 0.9
Oligomycin 0.0083 0.0087 1.1
Potassium cyanide 190, 145 190, 210 1.2
Rotenone 0.020 0.015 0.8
Miscellaneous/undefined
Aphidicolin 0.049 0.062 1.3
Bromophenacyl bromide 1.5, 0.36 1.3, 0.6 1.0
Ca2+ ionophore A23187 0.088 0.080 0.9
Chloroquine 12, 11 24, 7.2 1.4
Cyclocreatine 11400 11400 1.0
Cycloheximide 0.33 0.39 1.2
Cytochalasin B 0.94 1.4 1.5
Dimethylamiloride 69 70 1.0
Ouabain 0.052 0.032 0.6
Sulfonylurea LY295501 40 34 0.9
Tubercidin 0.10, 0.68 0.31, 0.092 2.4
aActivity was determined by 72 h growth inhibition assay (Coulter counts). bResistance factors (RF) calculated as
described in Materials and Methods. c± SD (n ³ 3).dnot significant (P > 0.05, Student’s t-test).1698 LA Skelton et al
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0.03 mM CB30865 for 1 and 4 h (data not shown). There was a
~50% reduction in [methyl-3H]dThd and [5-3H]Urd, but not
L-[4,5-3H]Leu, incorporation after 14 h exposure. This suggests
that CB30865 is not acting directly through DNA, RNA or protein
synthesis mechanisms.
Protection studies
With regard to HT29 and SW480 colon carcinoma cells, the
potency of CB30865 was not reduced in the presence of salvage-
able dThd (IC50 = 0.029 ± 0.0091 and 0.029 ± 0.018 mM respec-
tively). Similarly, the potency of CB30865 against MCF-7 cells
was not reduced in the presence of dThd/HX (IC50 = 0.0028 ±
0.00036 mM). Against the sensitive ovarian cell lines shown in
Figure 2, potency was also maintained in the presence of
dThd–HX (data not shown). An extended range of protection
studies was carried out using W1L2 cells. Cells were co-incubated
with CB30865 and various combinations of precursors and end
products of folate metabolism in order to determine whether the
growth inhibitory effects of this compound could be prevented. At
a concentration of 0.03 mM CB30865, cell number was reduced to
10–15% control after 72 h exposure even in the presence of
dThd–HX or LV (Figure 4). In addition, CB30865 retained this
potency in the presence of various combinations of dThd, HX, LV,
SAM, adenosine, guanosine, inosine, deoxycoformycin, methio-
nine and glycine (data not shown). These results suggest that
CB30865 exerts its growth inhibitory effect via a folate-indepen-
dent target. In contrast, the growth inhibitory effect of an equitoxic
concentration of CB300179 was reduced in the presence of dThd,
indicative of TS locus (Figure 4). In contrast, the activities of
ZD1694 (TS inhibitor) and MTX (DHFR inhibitor) were
prevented by dThd or dThd–HX respectively.
Generation of acquired resistance and cross-resistance
studies
The W1L2:R865 cell line was > 200-fold resistant to CB30865,
and resistance was stable for ~ 2 months (data not shown).
Representative growth inhibition curves for parent and resistant
lines are shown in Figure 5. The doubling time of the resistant line
was similar to the W1L2 parent (~ 18 h). Although the
W1L2:R865 cell line was cross-resistant in varying degrees to
other 3-pyridyl quinazolines which were structurally similar to
CB30865 (data not shown), no cross-resistance to any other agent
tested, of known or undefined mechanism of action, was observed
(Table 2).
Analysis of cellular DNA using propidium iodide
staining and flow cytometry
In W1L2 cells, at concentrations equivalent to ~ 10 ´ 72 h IC50
CB300179 (5.8 mM) and CB300189 (2.7 mM) induced cell cycle
effects consistent with TS inhibition, and thus DNA synthesis.
Representative histograms are shown in Figure 6A and B. After
only 4 h exposure, there was a decrease in the number of cells in
G2/M compared to controls. This is due to the division of cells in
G2, without the concomitant entry of S phase cells into G2. After
16 h exposure, cells began to build up in early S phase, and at this
time ³ 80% of the population was in S phase. There was a slow
progression of cells into mid S phase over the next 32 h. As
expected of TS inhibitors, when the cells were continuously
co-incubated with 10 mM dThd, or 10 mM dThd–25 mM HX, none
of the above effects were observed.
A different DNA histogram pattern was obtained with
CB30865, where this compound appeared to have very little effect
on the cell cycle (Figure 6C). For the 48 h that the cycle was
followed, the profiles were similar to controls, with no appreciable
changes in distribution. Similar DNA histograms were observed
CB300179
CB300179
+ dThd
CB30865
C
B
A
Figure 6 DNA histogram analysis of W1L2 cells exposed to 5.8 mM
CB300179 in the absence (A) and presence (B) of dThd or 0.03 mM CB30865
(C) over 48 h. Histograms obtained by fixing cells in 70% ethanol, incubating
with RNAse and propidium iodine for 30 min, and flow cytometric analysis: a,
control; b, 4 h; c, 16 h; d, 24 h; e, 48 hCytotoxic folic acid analogues with folate-independent locus 1699
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Panel/Cell line LgGI50 GI50
Leukaemia
CCRF-CEM
HL-60 (TB)
K-562
MOLT4
RPMI-8226
SR
Non-small cell lung cancer
A549/ATCC
EKVX
HOP-62
NCI-H226
NCI-H23
NCI-H322M
NCI-H460
NCI-H522
Colon cancer
COLO 205
HCC-2998
HCT-116
HCT-15
HT29
KM12
SW-620
CNS cancer
SF-208
SF-295
SF-539
SNB-75
U251
Melanoma
LOX-IMVI
MALME-3M
M14
SK-MEL-2
SK-MEL-28
SK-MEL-5
UACC-257
UACC-62
Ovarian cancer
IGROV1
OVCAR-3
OVCAR-4
OVCAR-5
OVCAR-8
SK-OV-3
Renal cancer
786-0
A498
ACHN
CAKI-1
RXF-393
SN12C
UO-31
Prostate cancer
PC-3
DU-145
Breast cancer
MCF7
MCF7/ADR-RES
MDA-MB-23/ATCC
MDA-MB-435
MDA-N
T-47D
MG-MID
Delta
Range
<–9.00
–6.81
<–9.00
–7.39
–8.21
–8.75
–6.83
>–5.00
–6.76
>–5.00
–6.87
–7.37
–6.64
–8.81
–7.63
<–9.00
–7.18
–8.01
<–9.00
<–9.00
–6.81
–7.30
<–9.00
–7.22
–6.76
>–5.00
<–9.00
–6.92
–6.63
–6.77
>–5.00
<–9.00
–8.28
–6.80
<–9.00
–6.30
–7.40
–8.06
>–5.00
–7.24
<–9.00
–8.07
>–5.00
>–5.00
>–9.00
<–9.00
<–5.00
–7.36
1.64
4.00
+3 +2 +1 0 –1 –2 –3
Figure 7 Mean GI50 graph showing the activity of CB30865 against the human tumour cell lines of the NCI in vitro drug discovery screen. Graph generated as
described in ‘Materials and Methods’. Bars extending to the right represent sensitivity of the cell line to CB30865 in excess of the average sensitivity of all tested
cell lines. Since the bar scale is logarithmic, a bar 2 units to the right implies CB30865 gave a GI50 for the cell line at a concentration 1/100th the mean
concentration required over all cell lines, and thus the cell line is unusually sensitive. Bars extending to the left correspondingly imply sensitivity less than the
mean. CNS, central nervous system1700 LA Skelton et al
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with the CH1 human ovarian carcinoma cell line, where 0.003,
0.015 and 0.075 mM CB30865 (equivalent to 2 ´, 10 ´ and
50 ´ IC50 as determined by 4-day MTT assay) did not induce any
gross changes in cell cycle distribution (data not shown).
Activity and ‘COMPARE’ analysis of CB30865 in the NCI
anticancer drug discovery screen
A representative mean GI50 graph for CB30865 is shown in Figure
7. CB30865 demonstrated particularly good activity against
leukaemia and colon tumour cell line panels, with GI50 values from
< 1 to 150 nM. Other panels, such as breast, ovarian and renal
cancers, as well as melanomas, showed variable responses to
CB30865, with GI50 values ranging from < 0.1 to > 1000 nM. With
respect to COMPARE analysis, all Pearson correlation coefficients
were < 0.55 (data not shown), and specifically, CB30865 gave a
correlation of 0.21 against the lipophilic TS inhibitor AG337.
These data are supportive of a non-TS locus for CB30865 and
suggest that this compound does not have a pattern of activity
consistent with known anti-tumour agents.
However, in some cell lines, growth inhibition values observed in
this screen (GI50) do not compare with other data presented in this
manuscript. For example, CB30865 inhibited SKOV3 cells with an
IC50 of 10 nM and a GI50 of ~ 500 nM. This could relate to the short
48 h exposure used in the NCI screen. Indeed, CB30865 was also
tested using a 6-day assay, and all GI50 values were < 10 nM.
DISCUSSION
The in vitro effects of the structurally related folate-based
compounds CB300179 (2-pyridine), CB30865 (3-pyridine) and
CB300189 (4-pyridine) have been compared. Whilst CB300179
and CB300189 displayed relatively poor growth inhibitory
potency, CB30865 was highly active in vitro against a number of
human tumour cell lines. However, despite being a potent inhibitor
of isolated TS (Ki = 110 nM), the data are consistent with CB30865
not inhibiting a known folate-dependent site within cells. This is
shown by its activity in the presence of salvageable dThd and
combinations of other precursors and end products of folate
metabolism. Furthermore, only CB30865 did not inhibit the flux
through TS in intact W1L2 cells. These, and other data, demon-
strate that CB30865 displays activity not typical of compounds
that target folate metabolism. For example, flow cytometric
studies demonstrated that DNA histograms showing typical effects
of TS inhibition were produced by CB300179 and CB300189
which were preventable by co-incubation with dThd. DNA
histograms derived from CB30865-treated W1L2 cells (at a cyto-
toxic concentration) showed no gross changes in distribution
compared to untreated cells. However, such analyses are limited in
that they produce a static profile at a given time and provide no
information about cycling kinetics. Extensive flow cytometric
studies using the continuous BrdUrd labelling technique (which is
a dynamic measurement), are published elsewhere (Skelton et al,
1998). These studies revealed that CB30865 had a major cell cycle
effect, in that cells arrested simultaneously in all phases of the
cycle after 20–24 h exposure. Therefore, CB30865 induced cell
cycle effects inconsistent not only with those of antimetabolites,
but also with other antineoplastic agents (which tend to cause
phase-specific arrest; Charcosset, 1986). For example, antifolates
such as methotrexate, trimetrexate and CB3717 (N10-propargyl-
5,8-dideazafolic acid) tend to cause accumulation of cells in
S phase or at the G1/S interphase (Taylor et al, 1981; Hook et al,
1986; Lorico et al, 1988). Agents which disrupt formation of the
mitotic spindle, such as the Vinca alkaloids, arrest cells in G2/M.
Secondly, a CB30865-resistant cell line (W1L2:R865) has been
generated which appears to possess a novel mechanism of resis-
tance. This cell line was sensitive to the large number of clinical
and experimental agents tested, including drugs from all the major
chemotherapeutic classes. This suggests that CB30865 may act via
a unique mechanism. In contrast, a cell line generated with
acquired resistance to the 2-pyridine derivative (CB300179) was
cross-resistant to other TS inhibitors, due to an increased TS
activity (~ 20-fold; Kobayashi et al, 1995). This cell line was not
cross-resistant to CB30865.
Furthermore, against the human tumour cell lines of the NCI in
vitro anticancer drug-discovery screen, CB30865 displayed a
pattern of activity which was not consistent with known anti-
tumour agents (i.e. it was ‘COMPARE-negative’). This again
suggests that CB30865 acts via a novel locus with respect to estab-
lished anticancer agents.
Further characterization of the CB30865-resistant cell line
should provide information as to the mechanism of action of this
compound. Using comparative genomic hybridization, prelimi-
nary results indicate that this resistant line has a multiple-fold
amplification on chromosome 7q22, and it is believed that identifi-
cation of the gene(s) involved will lead to an understanding of the
compound’s action.
In summary, CB300179, CB300189 and CB30865 represent a
series of related compounds differing only in the position of the
nitrogen in the pyridine ring, and this appears to dictate the mode
of action in cells. In particular, the 3-pyridine analogue CB30865
has been shown to be one of a class of highly potent, potential anti-
cancer agents, whose mechanism of action in vitro is inconsistent
with current anticancer agents. With cancer research currently
focused on the development of more effective drugs acting via
novel targets, the 3-pyridine derivative series, exemplified by
CB30865, represents an exciting prospect.
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